A 30 g/L veterinary-grade levamisole hydrochloride (Levasole) oral drench for ruminant herds is compounded in a jacketed 316L stainless steel vessel equipped with a counter-rotating anchor agitator and a bottom-mounted rotor-stator homogenizer. The API is charged into purified water at 20–25 °C under 1,200 rpm homogenizer speed. A pH electrode calibrated against Ph. Eur. 2.2.3 buffer solutions is used to confirm the solution remains within 3.8–4.2 after addition of dilute hydrochloric acid. A preservative system of methyl parahydroxybenzoate 1.8 g/L and propyl parahydroxybenzoate 0.2 g/L is pre-dissolved in 70 °C purified water and cooled to 35 °C before transfer. Sodium carboxymethylcellulose is dispersed at 0.35% w/v to raise kinematic viscosity to 80–120 mPa·s at 20 °C, measured with a Brookfield rotational viscometer spindle 62 at 100 rpm. The powder addition rate into the vortex must not exceed 2.5 kg/min; faster addition traps air and reduces preservative assay by 4–7% within 72 h. A nitrogen overlay at 0.2–0.5 bar positive pressure is applied when dissolved oxygen exceeds 2.0 mg/L. The bulk solution is passed through a 10 µm polypropylene depth filter followed by a 0.45 µm polyethersulfone capsule filter. Storage is in high-density polyethylene totes with light-protective outer cartons at 15–25 °C. The finished drench is filled into amber Type III glass or multilayer plastic bottles with induction-sealed caps. Release testing includes appearance, pH by Ph. Eur. 2.2.3, relative density by Ph. Eur. 2.2.5, microbial enumeration by Ph. Eur. 2.6.12 and 2.6.13, and assay by HPLC per Ph. Eur. monograph 0127. The formulation must not be mixed with alkaline electrolyte solutions or bicarbonate-containing oral rehydration fluids; pH above 5.8 precipitates levamisole base as fine crystals that do not redissolve under normal agitation.

Why Does Terminal Sterilization of Levamisole HCl 75 mg/mL Injections Demand Strict Nitrogen Headspace Control?

A 75 mg/mL multi-dose injectable solution for cattle and swine is prepared in a closed 316L stainless steel mixing system. Levamisole hydrochloride is dissolved in Water for Injections at 25–30 °C under low-shear turbine agitation. Benzyl alcohol is added at 1.5% v/v as a preservative; preservative effectiveness is verified by Ph. Eur. 5.1.3 challenge testing with Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. The formulation is adjusted to 3.5–4.5 with 0.1 M hydrochloric acid. Osmolality is brought to 280–320 mOsm/kg with sodium chloride and confirmed by a freezing-point osmometer. The solution is sparged with sterile-filtered nitrogen until dissolved oxygen remains below 1.0 mg/L. The batch is passed through a 0.22 µm sterilizing-grade polyvinylidene fluoride filter and filled into Type II glass vials with bromobutyl closures under an ISO 14644-1 Class C environment. Terminal sterilization is conducted at 121 °C for 15 min. Headspace oxygen above 2% after capping accelerates oxidative degradation of the preservative and produces a yellowish discoloration within 90 days at 40 °C/75% RH stability stress. Release testing includes particulate matter by USP 788, bacterial endotoxins by USP 85, sterility by Ph. Eur. 2.6.1, pH by Ph. Eur. 2.2.3, and assay by HPLC. The terminal sterilization step must not be applied to batches with pH above 5.0 because localized precipitation and vial surface deposition occur during the cooling phase. Loading patterns in the autoclave must avoid dense block stacking; validation thermocouple mapping covers the coldest vial location with a minimum F0 of 12 min.

A 50 g/kg levamisole hydrochloride medicated premix for growing swine is produced by first adsorbing the milled API onto precipitated silica at 1.0% w/w in a conical screw mixer for 10 min. The API fraction is precision-milled to a D50 of 180–220 µm and D90 below 350 µm. The carrier is washed corn cob granules with a D50 of 350–425 µm and moisture below 8.0% by Ph. Eur. 2.2.32. The adsorbed active phase is blended with carrier in a 1,000 L horizontal ribbon blender at 60–70% working volume for 15 min after color tracer confirms bulk distribution. Homogeneity is evaluated by sampling 10 thief points; acceptance is a relative standard deviation not greater than 5.0% and individual assays between 90% and 110% of label claim. The final premix is filled into high-density polyethylene woven sacks with a low-density polyethylene inner liner and stored at 25 °C and 60% RH or below. Carryover control uses a validated cleaning procedure with swab limit not exceeding 10 ppm levamisole HCl and rinse water determination by HPLC. Granulation is required when the premix is further compressed into mini-tablets or included in pelleted feed; a top-spray fluid-bed granulator with 1.2 mm two-fluid nozzle applies a 5% w/w povidone K30 binder solution at inlet air temperature 60–70 °C, product temperature 32–38 °C, and atomization pressure 1.5–2.0 bar. Final granule moisture is maintained below 3.0% to prevent mold growth and API hydrolysis. A process conflict arises when non-hydrophobic silica grades are omitted; electrostatic adhesion to the blender wall causes label claim drift of 6–10% after 30 min of mixing.

When Direct Compression of Levamisole HCl 150 mg Tablets Shifts from Microcrystalline Cellulose to Dibasic Calcium Phosphate Dihydrate

Direct compression of levamisole HCl 150 mg tablets for small-animal anthelmintic use is limited by a capping threshold when dibasic calcium phosphate dihydrate replaces microcrystalline cellulose 102 at 20% w/w filler level. A dry blend containing levamisole HCl 50.0% w/w, microcrystalline cellulose 102, crospovidone 4.0% w/w, colloidal silicon dioxide 0.5% w/w, and magnesium stearate 1.0% w/w is blended in a V-blender for 15 min at 75% fill. Magnesium stearate is added in a second 3 min blending step to avoid over-lubrication. Compaction on a 16-station rotary tablet press at main compression force 8–10 kN produces tablets with hardness 7–10 kp, friability below 0.8% by USP 1216, and disintegration below 15 min by USP 701. When DCP is introduced at 15% w/w to improve powder flow, the same compression force raises hardness to 13–15 kp, and dissolution in 0.1 M hydrochloric acid by USP 711 fails to reach Q 80% at 30 min. The failure is assigned to plastic deformation of the dihydrate and pore closure at the tablet core. Tablets falling below the dissolution limit show no disintegration failure, indicating dissolution is the controlling release test. For capsule dosage forms, levamisole HCl 150 mg is blended with pregelatinized starch and filled into size 3 hard gelatin capsules at target fill weight 240 mg and powder bed relative humidity 20–30%. Capsule shell moisture is equilibrated at 25 °C/35% RH for 24 h to reduce brittleness. Uniformity of dosage units must comply with USP 905 acceptance value ≤15.0. Residual solvents from any granulation step must meet VICH GL18 limits; impurity profiles are assessed against VICH GL11 thresholds.

Poultry drinking-water medication requires a 200 mg/g levamisole HCl soluble powder that remains free-flowing at 75% RH and dissolves in hard water within 2 min. The powder is dry-blended in a low-humidity suite at 20–25 °C and RH ≤30%. The carrier is anhydrous glucose with 0.5% w/w colloidal silicon dioxide and 0.2% w/w sodium lauryl sulfate. The mixing vessel is a 500 L double-cone blender filled to 60% working capacity. Dissolution is tested by adding 5 g product to 1 L tap water at 10 °C with paddle agitation 250 rpm; 90% of label claim must be recovered from a 0.45 µm filtrate within 5 min. Sachet filling is performed on a vertical form-fill-seal line using a four-layer foil laminate with an oxygen transmission rate below 0.5 cm³/(m²·24 h·atm). A desiccant sachet is inserted when bulk powder moisture by USP 921 exceeds 1.0%. The product is stored at 25 °C for a shelf life of 24 months; open sachet stability is 30 days at 30 °C/65% RH in a well-closed container. Hard water above 300 mg/L CaCO3 causes slight turbidity but no significant assay loss; published data for levamisole-specific metal-catalyzed degradation in poultry watering systems is limited.

Aquaculture Bath and Prolonged Immersion Pharmacokinetics

Immersion bath protocols for levamisole HCl in farmed fish are constrained by species-specific tolerance and local regulatory status. A 50 mg/L bath prepared in a 316L stainless steel tank is used for 2 h exposure in freshwater species under veterinary supervision where national approval exists. The stock solution is prepared by dissolving 50 g levamisole HCl in 100 L of hatchery water at 18–22 °C and pH 6.5–7.2. Aeration must maintain dissolved oxygen above 5.5 mg/L; simultaneous ozonation is not used because residual ozone oxidizes the imidazothiazole ring and reduces bath potency by more than 20% within 30 min. Fish are fasted for 12 h before immersion to reduce ammonia loading. At the end of exposure, the bath water is discharged through an activated carbon bed sized for 2 bed volumes per hour to capture residual levamisole before release. Published data for maximum residue limits, muscle depletion half-life, and species-specific withdrawal periods in aquaculture are not harmonized across jurisdictions; each production site must validate depletion under local regulation before harvest.